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Background: Pregnant women acutely infected with human parvovirus B19 (B19) may transmit the virus to the
developing fetus. The mechanism whereby the virus interacts with the placenta is unknown. It is known that
globoside receptor is required for successful infection of the target cells, which are the highly undifferentiated,
actively dividing colony and burst-form units of the erythroid series. Globoside is present on trophoblast cells
which have intimate contact with maternal blood, and may therefore serve as a potential route for B19
transmission into the fetal compartment.
Objectives: The purpose of this study was to determine whether B19 VP2 capsids could bind to villous
trophoblast cells in vitro and whether globoside was involved.
Methods: Binding of B19 VP2 empty capsid to ﬁrst-trimester villous trophoblast cells was assessed by multiple
approaches, including ICC using either biotinylated B19 VP2 empty capsid or unlabeled B19 VP2 empty capsid.
Quantiﬁcation of viral binding involved I
125-labeled B19 VP2 empty capsid. Competition studies included excess
unlabeled empty capsids or pretreatment with globoside-speciﬁc IgM antibody.
Results: Linear binding of B19 VP2 capsid to puriﬁed villous trophoblast cells in vitro was clearly demonstrated
(R
2=0.9524). Competition studies revealed speciﬁcity of I
125-labeled B19 VP2 capsid binding to villous
trophoblast cells when pretreatment with either 60-fold excess unlabeled B19 capsid or globoside-speciﬁc IgM
antibody took place. The results illustrated B19’s ability to bind in a speciﬁc manner to globoside-containing
villous trophoblast cells.
Conclusion: We speculate that the globoside present on trophoblast cells may play a role in viral binding in vivo,
which may facilitate B19 transmission across the maternal–fetal interface.
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Human parvovirus B19 (B19) was ﬁrst identiﬁed
in the sera of asymptomatic blood donors while
screening for hepatitis B virus
12. B19 is a non-
enveloped, linear, single-stranded DNA erythro-
virus within the Parvoviridae family
14. The plus-
and minus-sense strands of B19 DNA are
encapsidated individually during virus assembly
in the course of a permissive infection
13. The
5.5 Kb genome of B19 with its terminal inverted
repeats codes for two structural proteins, VP1 and
VP2, and a non-structural protein, NS1
32. The
NS1 protein is an early gene product that can be
expressed in permissive and in some non-
permissive cell types, and is associated with
cellular apoptosis
38. Complete viral replication is
limited to the highly undifferentiated, rapidly
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DOI: 10.1080/10647440400009912dividing erythroid progenitor cells of the colony-
forming unit (E-CFU) and the burst-forming unit
(E-BFU)
28. The cellular receptor necessary for
B19 infection is globoside, which is expressed to
high levels on human erythroid cells, making the
vast majority of individuals susceptible to B19
infection
6,7. Globoside is also expressed on some
non-erythroid cells, including megakaryocytes,
endothelium, fetal cardiomyocytes and tropho-
blast cells
20,36.
B19 inhibits haematopoetic colony formation
in vitro
28 and induces cell-cycle arrest in these cells
at the G2 phase,
27 both of which effects result in
acute anemia. In an infected fetus, the greatest risk
of sequelae from B19-induced anemia occurs
during the ﬁrst and second trimesters. This is
because of the large numbers of target erythroid
progenitor cells available then, coupled with the
relatively immature fetal immune system
39.
The virus binds to erythroid cells via the
globoside receptor
6. Individuals lacking globoside
on their red blood cells are not susceptible to B19
infection and have no detectable B19 antibodies
7.
Globoside is present on non-erythroid cell types
as well, including villous syncytiotrophoblasts and
extravillous and villous cytotrophoblasts
20. Pla-
cental globoside expression appears to be highest
in ﬁrst-trimester villous trophoblast cells; immu-
nohistochemical staining reveals diminished
globoside levels with increasing gestational
age
20. This ﬁnding is consistent with the greater
risk of poor outcome when B19 infection occurs
early in pregnancy
2,3. Trophoblast cells have
intimate contact with maternal blood: villous
syncytiotrophoblasts line the maternal blood
spaces and extravillous cytotrophoblasts invade
the maternal blood vessels
18. Both sites offer
potential routes for vertical transmission of B19
when a woman becomes infected during her
pregnancy.
The mechanism(s) for vertical transmission of
B19 are not known. It is unclear whether virus
can interact directly with trophoblast cells present
in the maternal–fetal interface to facilitate trans-
mission. The objective of this study was to
determine whether a baculovirus-expressed B19
VP2 empty capsid could bind ﬁrst-trimester
villous trophoblast cells in vitro and whether this
binding involved the globoside receptor.
MATERIALS AND METHODS
Procurement of tissue from ﬁrst-trimester
placentas
Permission to obtain anonymous ﬁrst-trimester
placentas for the purpose of isolating primary
villous trophoblast cells from elective pregnancy
terminations was granted by the Magee-Women’s
Hospital institutional review board. Placentas
from pregnancies being terminated because of
suspected infection were not included in this
evaluation.
Isolation and characterization of placental villous
trophoblast cells
Villous trophoblast cells (VTB) were isolated from
ﬁrst-trimester placentas using a slightly modiﬁed
procedure ﬁrst described by Kliman et al.
23
Brieﬂy, a 4–10 g sample of placental tissue was
minced and digested and the resulting cells
strained before separation on a Percoll (Sigma,
St Louis, MO) gradient. In some preparations,
cells were additionally treated with dispase
(Collaborative Biomedical Products, Bedford,
MA) to reduce the amount of extracellular matrix
present in the preparation and thus to enhance the
cell yield. Cells in a density of 1.053–1.060 g/ml
were collected off the gradient after centrifugation
at 400 6 g for 20 min at room temperarure
(RT), and used in subsequent experiments.
Leukocytes were selectively depleted from the
cell preparation as previously described
16. The
resultant leuko-depleted, trophoblast-enriched
placental cell preparations were characterized for
purity using ICC analysis individually for cyto-
keratin, globoside, CD45 and CD68 as described
in Table 1. At least 200 cells per slide were
counted among several ﬁelds at 6 200 to
calculate the percentage of immunoreactive cells
present within the VTB preparations.
VTB binding studies using biotinylated B19 VP2
empty capsids
Freshly isolated ﬁrst-trimester VTB (2.5 6 10
5)
were incubated in the presence or absence of
15 mg/ml biotin-labeled B19 VP2 empty capsid
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at 48C with constant rocking in 500 mlo f
capsid-binding medium, i.e. Iscove’s Modiﬁed
Dulbecco’s Medium (IMDM) (Gibco BRL,
Grand Island, NY) supplemented with 1% fetal
bovine serum (Gibco BRL), 1% (v/v) penicil-
lin–streptomycin (Cellgro, Gibco Brand Cell
Culture, Invitrogen, Grand Island, New York)
and 25 mol/l HEPES (Gibco BRL). IMDM is
commonly used when infecting cells in vitro
with B19
31,33,34. VTB were centrifuged at 520
6 g for 10 min at 48C. Cell pellets were
washed once in ice-cold IMDM before making
cytospin preparations of 2.5 610
5 cells per
slide. Cytospins were ﬁxed in ice-cold acetone
(4 min), and stored at 208C until analyzed,
when they were warmed to RT, rehydrated
through an ethanol series (100%–70%, 1 min
each) into PBS, treated with protein-blocking
agent (30 min, RT) and probed with 20 mg/ml
streptavidin-labeled FITC for 30 min at RT
(Vector Laboratories, Burlingame, CA). Mount-
ing medium containing propidium iodide
(Vector Laboratories, Birlingame, CA) was used
to visualize the cells.
VTB-binding studies using unlabeled B19 VP2
empty capsids
Freshly isolated ﬁrst-trimester VTB (2.5 6 10
5)
were incubated in the presence or absence of
15 mg/ml unlabeled B19 VP2 empty capsid in an
identical manner to that described for biotinylated
B19 VP2 empty capsids. Virus binding to VTB
was visualized using B19-speciﬁc IgG Mab that
recognizes the VP2 capsid protein (clone 5215D,
Chemicon International, Temecula, CA) as pre-
viously described
18.
I
125-labeling of B19 VP2 empty capsids
B19 VP2 empty capsids were visualized before
iodination, using transmission electron micro-
scopy (Center for Biologic Imaging, University of
Pittsburgh, PA) to conﬁrm their predicted
icosahedral shape and size (18–24 nm) expected
for intact assembled B19 virions
1,9. These self-
assembled, non-infectious B19 VP2 empty capsids
were generated using a baculovirus expression
vector (Biotrin International). B19 VP2 empty
capsids (25 mg/reaction) were labeled with I
125
using chloramine-T as described previously
17 at
the Iodination Core Facility, University of
Pittsburgh, PA. The reaction was terminated by
dilution in NaP04 buffer and separated on a
Sephadex column (Pharmacia, Pﬁzer, New Lon-
don, Connecticut). The average speciﬁc activity
of a given preparation was 13 mCi/mg capsid
protein, ranging from 8.6 to 19.4 mCi/mg. The
preparations of I
125-labeled B19 VP2 empty
capsid were always used in experiments within 2
weeks of the labeling reaction.
Binding of I
125-labeled B19 VP2 empty capsid to
VTB in vitro
VTB (2.5 6 10
5) were incubated at 48C for 1 h
with increasing amounts (0.05 mg to 2.0 mg) of
I
125-labeled B19 VP2 empty capsid in a total of
500 ml binding medium, consisting of PBS,
pH 7.4, with 1% BSA. The VTB-B19 capsid
mixture was centrifuged at 1000 6 g for 5 min at
48C. The resulting pellets were washed three
times in 1 ml binding medium at 48C and
resuspended in 1 ml fresh binding medium. The
radioactive counts per min (cpm) were measured
using a gamma counter. Each experiment con-
Table 1 Description of the Mab and ICC conditions used to characterize preparations of enriched VTB
Antigen Cell/virus target Mab clone Mab source Mab diln / inc cond.
Pancyto Cytotrophoblast AE1/AE3; IgG DAKO 1:100/30 min, RT
bHCG Syncytio None; IgG BioGenex 1:200/30 min, RT
Globoside Trophoblast AME-2; IgM NRC* 1:200/ON, 48C
CD45 Lymphocyte 2B11+PD7/26; IgG DAKO 1:100/30 min, RT
CD68 Macrophage KP1; IgG DAKO 1:400/30 min, RT
Mab, monoclonal antibody; ICC, immunocytochemistry; diln, dilution; inc cond, incubation conditions; pancyto, pancytokeratins; syncytio,
syncytiotrophoblast; none, none available; RT, room temperature; NRC*, Netherlands Red Cross (50); ON, overnight
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equal volumes of I
125-labeled capsids added to
tubes without cells, which was used to estimate
the non-speciﬁc binding. All data points were run
in triplicate, with the experiment performed three
times. Because each experiment used a different
batch of iodinated B19 VP2 capsid preparation,
averages could not be calculated and error bars
could not be included.
To address binding speciﬁcity, we performed
competition studies using either excess unlabeled
B19 VP2 empty capsid, or pretreatment of VTB
with globoside-speciﬁc IgM monoclonal anti-
body. The excess cold capsid competition studies
were carried out using VTB (2.5 6 10
4)
incubated in binding medium at 48C for 1 h
with constant rocking, either alone or with 30-
fold or 60-fold excess unlabeled B19 VP2 empty
capsid. Subsequently the VTB–capsid mixtures
were incubated at 48C for 1 h with 750 ng I
125-
labeled B19 VP2 empty capsid. VTB–capsid
mixtures were centrifuged at 1000 6 g for
5 min at 48C, washed twice in 1 ml cold binding
medium and resuspended in 1 ml fresh binding
medium. The radioactive cpm was measured
using a gamma counter. Each experiment con-
tained a no-cell control, consisting of 750 ng I
125-
labeled capsids without cells, which was used to
estimate non-speciﬁc binding. All data points
were run in triplicate and the experiment was run
twice with 30X and 60X excess cold capsid and a
third time with only 60X excess.
The competition experiment using the glo-
boside-speciﬁc IgM antibody pretreatment of
VTB (2.5 6 10
5) was conducted in binding
medium incubated overnight at 48C with
constant rocking without IgM antibody pre-
treatment (positive control), with 100 ng of
globoside-speciﬁc IgM murine monoclonal anti-
body, or with an equal concentration of a non-
relevant IgM murine monoclonal antibody
(negative control). After overnight incubation,
1.5 mgI
125-labeled B19 VP2 empty capsids
were added and incubated at 48C for an
additional 1 h with constant rocking. Cells
were pelleted at 1000 6 g for 5 min, washed
twice and centrifuged again at 1000 6 g for
5 min. The ﬁnal cell pellet was resuspended in
1 ml cold binding medium and the radioactive
cpm per tube measured. All data points were
analyzed in triplicate, and the competition
experiment was performed twice.
Statistical analysis
Differences between treatment means were
analyzed using unpaired T-test (InStat for Mac-
Intosh, 1993 Graph Pad Software Version 2.01).
For competition experiments, data was log
transformed and Kruskal-Wallis Nonparametric
ANOVA test and Dunn’s Multiple Comparison’s
post-test were applied. A ‘‘p’’ value of 50.01 was
considered signiﬁcant.
RESULTS
Characterization of freshly isolated ﬁrst-
trimester VTB
The vast majority (93–100%) of cells isolated from
ﬁrst-trimester placentas (9–13 weeks’ gestation)
(n=8) were cytotrophoblast in nature, staining
positive for pancytokeratins (data not shown). In
contrast, contaminating leukocytes (CD45) or
macrophages (CD68) constituted 0.0–5.0% and
0.0–7.0% of the total cells, respectively (data not
shown). Most puriﬁed cells (53–79%) also
expressed globoside
20.
B19 VP2 empty capsid-induced VTB aggregation
B19 virus is known to induce red blood cell
aggregation via the globoside receptor
5. First-
trimester VTB incubated in the presence of B19
VP2 empty capsid at room temperature for 1 h
demonstrated this property also, compared with
VTB incubated in diluent alone. Figure 1
illustrates a typical cell aggregation pattern seen
when 2.5 6 10
5 VTB were incubated in the
presence or absence of 15 mg B19 VP2 empty
capsid. This agglutination reaction occurred
rapidly after the addition of virus capsid to VTB.
B19 VP2 empty capsid-bound ﬁrst-trimester
VTB in vitro
The ability of B19 VP2 empty capsid to bind ﬁrst-
trimester VTB was assessed by several approaches,
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biotinylated B19 VP2 empty capsid or unlabeled
B19 VP2 empty capsid. Quantiﬁcation of viral
binding entailed I
125-labeled B19 VP2 empty
capsid.
A streptavidin-labeled FITC probe (Vector
Laboratories) was used to visualize directly
biotinylated B19 VP2 capsid binding to VTB.
Biotinylated B19 VP2 empty capsid (15 mg)
bound to the majority of VTB was distributed
over the slide, either as individual cells or as cell
aggregates (Figure 2a). The bright green staining
was present on the surface of the cells; only the
red staining, due to the propidium iodine
counterstain, was observed on VTB in the
absence of B19 VP2 empty capsid (Figure 2b).
A similar pattern of VTB staining as a result of
capsid binding was seen when applying unlabeled
B19 VP2 empty capsid, and antigen was visua-
lized using a B19-speciﬁc IgG Mab recognizing
the VP2 capsid antigen as previously described
18.
VTB staining was absent when either B19 VP2
empty capsid was excluded from the experiment
or when a non-immune serum was used in place
of the B19-speciﬁc VP2 IgG Mab (data not
shown).
Quantiﬁcation of I
125-labeled B19 VP2 capsid
bound to ﬁrst-trimester VTB
Figure 3 illustrates the binding kinetics of B19
VP2 empty capsid with VTB. I
125-labeled B19
VP2 empty capsid bound VTB (2.5 6 10
5) in
vitro in a linear manner (R
2=0.9524); however,
saturable binding was not consistently achieved.
Similar kinetics were seen regardless of whether
the binding was allowed to proceed for 1 h or 2 h
at 48C (data not shown). Non-speciﬁc binding
(Ficoll hypaque puriﬁed leukocytes) represented
approximately 10% of the total binding at the
highest amount of iodinated B19 VP2 empty
capsid used (2 mg) (data not shown).
Binding of I
125-labeled B19 VP2 empty capsid to
ﬁrst-trimester VTB was reduced in the presence
of60-foldexcessunlabeledB19VP2emptycapsid
Figure 4 illustrates the decrease in I
125-CPM
associated with VTB pretreated with 60-fold
(60X) excess unlabeled B19 VP2 empty capsid
compared with VTB alone without pretreat-
ment. Because of the limited availability of B19
VP2 empty capsid, competition studies were
Figure 1 B19 VP2 empty capsid-induced VTB aggregation. Equal numbers of VTB (2.5 6 10
5) were incubated with
(a) or without (b) 15 mg/ml unlabeled B19 VP2 empty capsid before cytospin preparation and hematoxylyn
counterstaining
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4)
compared with the original quantitative binding
studies using 2 6 10
5 VTB illustrated in Figure
3. VTB (2 6 10
4) pre-incubated alone or with
60-fold excess of unlabeled B19 VP2 empty
capsid were then combined with 750 ng I
125-
labeled B19 VP2 empty capsid. All data points
were run in triplicate within an experiment. The
experiment was repeated three times, twice with
30X and 60X excess unlabeled capsid, and a
third time with 60X excess only. Figure 4
illustrates the mean cpm values. The one-way
ANOVA demonstrated a signiﬁcant difference
between the mean of the VTB alone (25162 +
8531 SD) compared with that of the VTB +
60X excess unlabeled capsid (6681 + 1116 SD)
at p=0.0078. Figure 4 also illustrates the
effectiveness of the 60X excess unlabeled capsid
competition, as these levels were similar to the
mean of the non-speciﬁc binding control (8580
+ 1192 SD).
Pretreatment of ﬁrst trimester VTB with a
globoside-speciﬁc IgM antibody resulted in
reduced I
125-labeled B19 VP2 capsid binding
Figure 5 illustrates the level of speciﬁc binding
associated with 2.5 6 10
5 VTB after treatment
Figure 2 Evidence for B19 VP2 empty capsid bound to VTB. Biotinylated B19 VP2 empty capsids (15 mg/ml) were
added to freshly isolated VTB. (a) Capsid binding was detected directly using streptavidin-labeled FITC (green). (b)
Cells without added capsid revealed propidium iodine counterstain only (red)
Figure 3 Binding of I
125-labeled B19 VP2 empty capsid
to VTB in vitro. Increasing amounts (50 ng–2 mg) of I
125-
labeled B19 VP2 empty capsid were added to 2.5 6 10
5
VTB per reaction. Cell-speciﬁc binding was deﬁned as
total counts per minute (cpm) less the non-speciﬁc cpm
present in the no-cell control. Data points were
analyzed by linear regression and the correlation
coefﬁcient (R
2=0.9524) was calculated
Figure 4 Effect of excess unlabeled B19 VP2 empty
capsid on binding of I
125-labeled B19 VP2 empty capsid
to VTB. I
125-labeled B19 VP2 empty capsid (750 ng) was
added to 2.5 6 10
4 VTB (VTB alone), and this binding
was competed for using 60-fold excess unlabeled B19
VP2 empty capsid (VTB + 60X capsid). Differences
between the calculated means of VTB alone and that of
the 60-fold excess unlabeled capsid competition experi-
ment were statistically different (p50.01). Error bars
represent the standard deviation of the means
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with 2 mgI
125-labeled B19 VP2 capsid, compared
with VTB without antibody pretreatment or
VTB pretreatment with a non-speciﬁc IgM
antibody. The difference in speciﬁc binding was
highly signiﬁcant (p=0.0004). The level of
counts associated with the no-cell control was
less than 10% of the speciﬁc binding (data not
shown).
DISCUSSION
The data presented here provide the ﬁrst in vitro
evidence for binding of human parvovirus B19 to
placental villous cytotrophoblast cells via the
globoside receptor. There is precedent for B19
binding to globoside receptors on other non-
erythroid cell types, including 293 cells, HeLa
cells, human umbilical vein endothelial cells and
normal human lung ﬁbroblasts. In the latter study
using ﬁbroblast cells, the investigators point out
that the level of globoside expression did not
correlate with efﬁciency of binding, and they
postulate that although globoside is necessary for
B19 binding, it may not be sufﬁcient for viral
entry into cells
37.
Other investigators suggest that multiple glyco-
sphingolipids determine B19 tissue tropism
11.W e
have shown previously that multiple glycolipids,
including globoside, are present on villous
syncytiotrophoblasts and cytotrophoblasts
20.
These related glycolipids may act as co-receptors
for B19 binding to trophoblast cells.
This study further served to emphasize the
success of substituting baculovirus-expressed B19
VP2 empty capsid for infectious virus, being
similar in size, shape and immunoreactivity to the
native virus, which is available in very limited
quantities
1,9. These recombinant B19 capsids have
been shown to be similar to the native B19 virion
as well, in their ability to inhibit fetal haemato-
poetic colony formation in vitro
24. We also
observed the phenomenon of villous trophoblast
cell aggregation that was induced by B19 VP2
empty capsid addition, an event described by
Brown et al.
5 for red blood cell hemagglutination
in the presence of B19 capsids.
It should be noted that the binding studies
described here used primary villous cytotropho-
blast cells, and not villous syncytiotrophoblast
cells. For the purposes of assessing viral binding,
villous cytotrophoblasts were easier to isolate and
enumerate compared with syncytiotrophoblast
cells, and did not require culturing before
experimentation. The inclusion of syncytiotro-
phoblasts would be much more critical in a study
of viral transport across the placental barrier as
opposed to assessment of viral binding. Therefore,
for the purposes of this investigation, villous
cytotrophoblasts were an acceptable model for
viral binding. These cells contain the membrane-
bound globoside receptor and are the cells whose
membranes fuse to form the villous syncytiotro-
phoblast layer of the placenta.
The results of the competition studies sug-
gested that viral binding to villous trophoblast
cells was speciﬁc; signiﬁcant reduction in viral
binding was observed after pretreatment either
with 60-fold excess unlabeled capsid or with
globoside-speciﬁc IgM. Although the in vitro
B19 capsid-binding to trophoblast cells was
linear (R
2=0.9524), we were unable consis-
tently to demonstrate saturable binding kinetics
under the incubation conditions in our study.
The observation argues against a speciﬁc recep-
tor-mediated binding, but we believe this may
be due to the limited amount of labeled B19
VP2 empty capsid used in each of the experi-
ments as well as the natural variation in
globoside content that exists between individual
*
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P
M
Figure 5 Effect of globoside antibody pretreatment on
VTB binding of I
125-labeled B19 VP2 empty capsid. Equal
numbers (2.5 6 10
5) of VTB were either untreated
(black bar), or pretreated with 10 mg globoside IgM Mab
(hatched bar), or with 10 mg non-speciﬁc IgM Mab
(white bar) before incubation with 1.5 mgI
125-labeled
B19 VP2 empty capsid. Error bars represent standard
deviation of the means
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capsid concentrations binding saturation might
have been demonstrated more consistently, as
described by Brown et al.
6 Alternative explana-
tions might include virus use of additional
receptors for binding, present on VTB. These
receptors may include other glycosphingolipids
known to be present on VTB
20, or a second
unrelated co-receptor yet to be identiﬁed.
However, it is clear from the data presented
here that B19 capsids do bind to placental
trophoblast cells. This is an important observa-
tion in the effort to begin to understand how
B19 virions interact at the maternal–fetal inter-
face of the placenta.
Although we have suggested a role for globo-
side receptor in viral binding to trophoblast cells,
our data do not address B19 entry into cells. The
question still remains: how does B19 virus cross
the placental barrier? We are currently investigat-
ing the possibility that transplacental transfer
occurs via B19-induced trophoblast cell damage
and hence a breakdown of the placental barrier.
B19-induced cellular apoptosis has been described
in both permissive and non-permissive cell
types
10,25,29,38. Damage to the trophoblast cell
layer surrounding the placenta would compro-
mise the integrity or function of the placenta,
particularly in the ﬁrst trimester when active
reconstruction of the placental syncytiotropho-
blast barrier is occurring
30.
We have recently described an increase in the
number of apoptotic syncytiotrophoblast and
cytotrophoblast cells within B19-infected placen-
tas isolated from pregnancies with poor fetal
outcome, compared with B19-infected placentas
isolated from pregnancies with good fetal out-
come or from age-matched, uninfected control
placentas
19. The higher apoptotic indices seen in
these cell types were visualized using the M30
CytoDeath antibody (Roche Molecular, Indiana-
polis, IN), which speciﬁcally detects apoptosis-
induced cleavage of cytokeratin 18
8,21.
Other means of B19 transfer across the placenta
that warrant investigation include receptor-
mediated endocytosis
11,20, through the FC recep-
tor present on syncytiotrophoblast cells
4 or, due
to its small size, passive diffusion using cell
channels or pores within trophoblasts
15,22.
In summary, the results presented here have
documented B19-binding to villous trophoblast
cells, key cell types located at the maternal–fetal
interface. A much better appreciation of how
B19, a virus that is present in blood of infected
individuals, interacts with the trophoblast cell is
needed before we can understand the mechan-
ism(s) by which B19 gains access to the fetal
compartment. Ultimately, knowing how the virus
crosses the placenta will allow us to develop
approaches that may inhibit this damaging process
during pregnancy.
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